Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia

Cancer Epidemiology Research Program (CERP), Institut Català d'Oncologia - Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat (Barcelona), Spain.
Vaccine (Impact Factor: 3.62). 09/2008; 26 Suppl 10(Suppl 10):K1-16. DOI: 10.1016/j.vaccine.2008.05.064
Source: PubMed


Worldwide human papillomavirus (HPV) prevalence in women with normal cytology at any given point in time is approximately 10% indicating that HPV is one of the most common sexually transmitted infections. HPV-16 is consistently the most common type and HPV-18 the second with some minor regional differences. Furthermore, across the spectrum of cervical lesions, HPV-16 is consistently the most common HPV type contributing to 50-55% of invasive cervical cancer cases strongly suggesting that this viral type has a biological advantage for transmission, persistency and transformation. The same phenomenon is observed albeit at a lower level for HPV-18 and HPV-45. Sexual behavioral patterns across age groups and populations are central to the description of the HPV circulation and of the risk of infection. The concept of group sexual behavior (in addition to individual sexual behavior) is important in exploring HPV transmission and has implications for defining and monitoring HPV and cancer prevention strategies. In natural history studies, the pattern of HPV DNA prevalence by age groups is similar to the patterns of HPV incidence. Rates of exposure in young women are high and often include multiple types. There is a spontaneous and rapid decrease of the HPV DNA detection rates in the middle-age groups followed by a second rise in the post-menopausal years. This article reviews: 1) the evidence in relation to the burden of HPV infections in the world and the contributions of each HPV type to the spectrum of cervical cellular changes spanning from normal cytology to invasive cervical cancer; 2) the critical role of the patterns of sexual behavior in the populations; and 3) selected aspects of the technical and methodological complexity of natural history studies of HPV and cervical neoplasia.

65 Reads
  • Source
    • "Moreover, HPV-33 and 31 have high prevalences in some regions (Jin et al., 2010). In the current study, HPV-16, 52, 58 and 33 were the most common types among Tibetan and Naxi women; these findings are in line with previous research (Mayineur et al., 2011, Bosch et al., 2008, Li et al., 2008). Among Han women, HPV-33 (5.1%) is the most common genotype, followed by HPV-58, 16, and 52. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The prevalence and genotype distribution of human papillomavirus (HPV) vary throughout the world. To assess the prevalence and genotype distribution of HPV among three ethnic groups in two geographic locations in northwestern Yunnan, we recruited 522 women in Shangri-le (n=255) and Lijiang (n=267). PCR amplification of HPV DNA was performed on cervical cells from these women using two consensus primer systems (MY09/11 and GP5/6). Amplified HPV DNA was genotyped using the HPV GenoArray test. Geographically, the HPV prevalence was significantly higher (P=0.002) among Shangri-le women than among Lijiang women. Infections with high-risk (HR)-HPV and with multiple HPV genotypes were also significantly more common (P=0.001) among women in Shangri-le than women in Lijiang. Additionally, the prevalence of overall, HR-HPV, and single genotype HPV infections was significantly higher (P=0.001) among Tibetan women than among Naxi and Han women. HPV-16 and HPV-33 were significantly more frequent in Shangri-le women compared with Lijiang (P=0.006) women. In addition, HPV-16 (9.81%) and HPV-33 (5.88%) were significantly more prevalent in Tibetan women than in Naxi and Han women. Here, for the first time, we highlight the significant variation in the prevalence and genotype distribution of HPV in various populations in the north-western region of Yunnan Province. This article is protected by copyright. All rights reserved.
    Journal of Medical Virology 08/2015; DOI:10.1002/jmv.24352 · 2.35 Impact Factor
  • Source
    • "However, there remain around 500,000 new cases of cervical cancer each year worldwide, which results in about 274,000 deaths (Parkin et al., 2005). HPV-16 is present in around 50% of all cervical cancers (Bosch et al., 2008), and it is by far the most prevalent high-risk mucosal HPV. Consequently, the development of prophylactic vaccines to reduce HPV infections has mainly focused on this HPV genotype. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Human papilloma virus (HPV)-16 is the prevalent genotype associated with cervical tumours. Virus-like-particle-based vaccines have proven to be effective in limiting new infections of high-risk HPVs, but their high cost has hampered their use, especially in the poor developing countries. Avipox-based recombinants are replication-restricted to avian species and represent efficient and safe vectors also for immunocompromised hosts, as they can elicit a complete immune response. A new fowlpox virus recombinant encoding HPV-L1 (FPL1) was engineered and evaluated side-by-side with a FP recombinant co-expressing L1 and green fluorescent protein (FPL1GFP) for correct expression of L1 in vitro in different cell lines, as confirmed by Western blotting, immunofluorescence, real-time PCR, and electron microscopy. Mice were also immunised to determine its immunogenicity. Here, we demonstrate that the FPL1 recombinant better expresses L1 in the absence of GFP, correctly assembles structured capsomers into virus-like particles (VLPs), and elicits an immune response in a preclinical animal model. To our knowledge, this is the first report of HPV VLPs assembled in eukaryotic cells using an avipox recombinant. Copyright © 2015. Published by Elsevier B.V.
    Antiviral Research 02/2015; 116. DOI:10.1016/j.antiviral.2015.01.012 · 3.94 Impact Factor
    • "The pioneering research work of Professor Harald zur Hausen in the 1970s focused on the potential causal association between the human papilloma virus (HPV) and cervical cancer. Today, this causal association has been firmly established; HPV infection is a necessary but not sufficient condition for the development of cervical cancer (Holowaty et al., 1999; Zur Hausen, 2000; Muñoz et al., 2003; Bosch et al., 2008; De Sanjose et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study was to assess the overall prevalence of the human papilloma virus (HPV) infection and distribution of high-risk HPV (hrHPV) types in Greece and evaluate the participation of women in primary and secondary cervical cancer prevention. This was a prospective, cross-sectional study carried out between October 2005 and January 2011 in Greece; 5379 women filled out the study questionnaire anonymously. 5107 women underwent cervical HPV-DNA testing, either by Hybrid Capture 2, followed by restriction fragment length polymorphism-PCR, or by the Abbott Real-Time High-Risk HPV test. Overall, 5.8% (295/5107) of women were positive for hrHPV infection. The most common hrHPV type was HPV-16 (24.8% among infected women; 1.4% overall), followed by HPV types 31, 35, 53, 18, 51, 56, 58, 52, 39, 66, 45, 33, 59, and 68. In respect to primary prevention of cervical cancer, acceptance of anti-HPV vaccination appeared to decrease over time (from 85-89.9% annually during 2005-2008 to 64.4-60.5% during 2009-2010, P<0.001). In respect to secondary prevention, only 30.3% of women had regular (annually for more than 5 years) Pap smears; regular gynecologic examinations, Papanicolaou testing, and knowledge of HPV were all associated with various demographic parameters (age, education, place of residence, occupation, and income). The prevalence of hrHPV infection in Greece is similar to that in other European countries; the most common type is HPV-16. The initially relatively high acceptance of HPV vaccination decreased after licensing of the vaccine. Demographic parameters appear to influence participation in cervical cancer screening.
    European Journal of Cancer Prevention 09/2014; 23(5). DOI:10.1097/CEJ.0000000000000060 · 3.03 Impact Factor
Show more